Theriva™ biologics announces presentation at esmo congress 2023 featuring survival outcomes in phase 1 study evaluating vcn-01 in combination with durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

-results from investigator-sponsored study in collaboration with the institut catala d'oncologia (ico) show enhanced patient survival, correlating with vcn-01 induced upregulation of pd(l)-1-

TOVX Ratings Summary

TOVX Quant Ranking